ENHERTU Receives Japanese Approval for HER2-Low Breast Cancer
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
On June 27, 2022, Daiichi Sankyo Co., Ltd. announced that its HER2-antibody-drug conjugate ENHERTU has received manufacturing and marketing approval in Japan for an additional indication: patients with HER2-low breast cancer.
Breast cancer is the most common cancer among women in Japan, with approximately 90,000 cases reported in 2020. HER2 is a protein expressed on the surface of cancer cells and is also present in gastric, colorectal, and lung cancers. Approximately half of breast cancer patients have HER2-low expression, and there were previously no antibody-drug conjugates targeting this group.
This approval is based on the results of the DESTINY-Breast04 Phase III clinical trial. The trial compared ENHERTU (N=557) with physician's choice of chemotherapy (N=373) in patients with previously treated HER2-low breast cancer. The results showed that both hormone receptor-positive patients and the overall patient population achieved significant improvements in progression-free survival (PFS) and overall survival (OS).
Daiichi Sankyo stated in its press release that the approval provides a new treatment option for HER2-low breast cancer patients and will contribute to the treatment of more breast cancer patients in Japan.
The results of the DESTINY-Breast04 trial were also presented at the American Society of Clinical Oncology (ASCO 2022) and published in the medical journal "The New England Journal of Medicine."
Source: https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202206/20220627_J2.pdf
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4